Christopher Chan, DO
Pulmonary Disease · Acworth, GANPI 1972998730
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $34,218 of the $50,759 with a category attached, or 67.4%. AstraZeneca accounts for 68.7% of it on its own, with 30 other manufacturers making up the rest. 2025 is the largest year on record at $46,464, more than ten times the $647 reported in 2019. Among pulmonary disease clinicians in GA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 258 payments — averaging $196.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$35K
- Boehringer Ingelheim$8K
- Sanofi$4K
- GSK$909
- Grifols USA, LLC$443
- Inari Medical, Inc.$382
- plus $2K from 25 others
What the payments were for
- Consulting fees$6,40413%
- Speaking & faculty fees$34,21867%
- Travel & lodging$2,3005%
- Food & beverage$7,68915%
- Education$1480%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 70 | $34,856 |
| Boehringer Ingelheim | 42 | $8,182 |
| Sanofi | 16 | $4,209 |
| GSK | 45 | $909 |
| Grifols USA, LLC | 22 | $443 |
| Inari Medical, Inc. | 2 | $382 |
| Insmed, Inc. | 2 | $227 |
| Regeneron Healthcare Solutions, Inc. | 8 | $199 |
| Mylan Specialty L.p. | 6 | $147 |
| Fisher Scientific Company L.L.C. | 2 | $140 |
| La Jolla Pharmaceutical Company | 2 | $131 |
| Verona Pharma, Inc. | 6 | $121 |
| ANI Pharmaceuticals, Inc. | 5 | $104 |
| Cumberland Pharmaceuticals, Inc. | 1 | $89 |
| Amgen | 4 | $89 |
| Pfizer | 3 | $72 |
| Baxter Healthcare | 2 | $57 |
| Inspire Medical Systems, Inc. | 1 | $54 |
| Jazz Pharmaceuticals Inc. | 3 | $52 |
| Viatris Specialty LLC | 2 | $51 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $41 |
| Pulmonx Corporation | 2 | $31 |
| Inogen, Inc. | 2 | $28 |
| ZOLL Circulation Inc | 1 | $27 |
| ADMA Biomanufacturing LLC | 1 | $24 |
| Axsome Therapeutics, Inc. | 1 | $23 |
| Merck | 1 | $16 |
| Resmed Corp | 1 | $15 |
| Teva Pharmaceuticals USA, Inc. | 1 | $15 |
| Lilly USA, LLC | 1 | $14 |
| Paratek Pharmaceuticals, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BREZTRI$33,168
- OFEV$4,410
- QFITLIA$3,774
- FLOWTRIEVER CATHETER, S$382
- CT THROMBECTOMY SYSTEM KIT$382
- NUCALA$238
- Arikayce$128
- TEZSPIRE$126
- FASENRA$125
- GIAPREZA$116
How this compares
$50,759 in reported general payments places this provider in the 90th percentile of 365 pulmonary disease providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 179 | $164,266 |
| OfevNintedanib Esylate | 12 | $157,516 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 53 | $44,100 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 55 | $33,682 |
| Spiriva RespimatTiotropium Bromide | 31 | $24,058 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 32 | $22,227 |
| EliquisApixaban | 18 | $10,698 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 43 | $7,038 |
| Advair HfaFluticasone Propion/Salmeterol | 14 | $5,978 |
| Breo ElliptaFluticasone/Vilanterol | 11 | $5,922 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 216 | $4,531 |
| SymbicortBudesonide/Formoterol Fumarate | 20 | $4,526 |
| Ventolin HfaAlbuterol Sulfate | 32 | $2,104 |
| Wixela InhubFluticasone Propion/Salmeterol | 20 | $1,796 |
| Azelastine Hcl | 35 | $903 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Stiolto Respimat, Spiriva Respimat | $8,182 | $215,25698 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta | $909 | $192,415222 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $34,856 | $48,62673 claims |
| PfizerEliquis | $72 | $10,69818 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 365 pulmonary disease providers in Georgia.
Other pulmonary disease in Acworth
- Juan ArmstrongAcworth$21K
- Lawrence McDermottSavannah$963K
- Vivek SambharaGainesville$417K
- Chad MillerAustell$382K
- Nehal BhattAthens$371K
- Maria MascoloRincon$358K
- Colin SwensonAtlanta$255K
- David MillerDecatur$206K
- Michael MullinsSavannah$132K
- Hitendra PatelMarietta$104K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.